P21 with Adamantane
EmergingAdamantane-modified P21 peptide
P21 with Adamantane is supplied as a modified peptide research compound for qualified laboratory and B2B applications. Research interest focuses on the effect of adamantane conjugation on peptide properties, biological activity, and CNS-related delivery. Specific performance depends on the molecular construct and experimental conditions.
Mechanism of Action
P21 operates through multiple pathways: it inhibits leukemia inhibitory factor (LIF) signaling, removing a key roadblock to neurogenesis and shifting the brain toward a more embryologic state favoring neuron growth. It increases brain-derived neurotrophic factor (BDNF) expression and activates the BDNF/TrkB/PI3-K/AKT/GSK3β pathway. The adamantane modification is investigated for its potential influence on physicochemical properties and CNS-related delivery characteristics.
Key Benefits
Molecular Data
Dosing Protocols
| Goal | Dose | Frequency | Route |
|---|---|---|---|
| Research protocol | Variable by study | Daily | SubQ or IP |
Research Indications
Peptide Chemistry
Used in research investigating the effect of adamantane modification on peptide physicochemical and biological properties.
Neuroscience
Investigated as a modified peptide construct for research into CNS-related delivery characteristics.
Neurobiology
Provides a modified P21 construct for comparative research against unmodified P21.
Peptide Interactions
Different nootropic mechanisms; may complement each other.
Both promote neurogenesis through different pathways.
No known negative interactions; different mechanisms.
Different cognitive enhancement mechanisms.
What to Expect
Side Effects & Safety
Common (Generally Mild)
- •Limited data - primarily preclinical research
- •Generally well-tolerated in animal studies
Stop Signs (Seek Medical Attention)
- ⚠Allergic reactions
- ⚠Unusual neurological symptoms
Contraindications
- ✕Not approved for human use
- ✕Pregnancy or breastfeeding
- ✕Unknown safety profile in humans
Quality Checklist
Good Signs ✓
- White lyophilized powder
- Clear solution after reconstitution
- High purity (>95%)
- Intact vacuum seal
Warning Signs !
- Research chemical - limited quality standards
Bad Signs ✕
- Discoloration
- Cloudy solution
- Particulates visible
References
P021 markedly reduced tau pathology, attenuated Aβ, rescued episodic memory, and reduced mortality in AD mice.
Disease-modifying effect via BDNF/TrkB/PI3-K/AKT/GSK3β pathway; rescued neurogenesis and cognition.
May reduce age-related cognitive decline by restoring BDNF expression and synaptic function.
Beneficial effects in preclinical studies make P21 highly promising for AD drug development.
FAQs
What is P21 with Adamantane?
P21 with Adamantane is a modified form of P21 in which an adamantane moiety is incorporated into the peptide construct.
How is it different from P21 without Adamantane?
P21 without Adamantane is the unmodified peptide, whereas P21 with Adamantane contains an additional adamantane modification. This results in different molecular structures and physicochemical properties.
Does the adamantane modification guarantee blood-brain barrier penetration?
No. Adamantane modification may be investigated for its influence on CNS-related delivery, but BBB penetration should not be assumed or guaranteed without construct-specific experimental evidence.
Has P21 with Adamantane been clinically tested?
Human clinical safety and efficacy data have not been established for this research compound.
